Resources
These essential resources contain important information to minimise the risk of meningococcal infection associated with zilucoplan.
The patient or, if appropriate, their caregiver should be educated about treatment risks and provided with a Patient Alert Card. It is important for patients treated with zilucoplan to carry the Patient Alert Card with them at all times throughout treatment and for two months after their last dose.
Please refer to the Summary of Product Characteristics for more detailed safety information about zilucoplan.
You have selected Greece (Greek).
Change your desired country and language here
IMPORTANT INFORMATION
Vaccination Confirmation
To minimise the risk of potential meningococcal infection with ZILBRYSQ (zilucoplan), ZILBRYSQ can be dispensed only after written confirmation that the patient has received meningococcal vaccination. The supplier will not be able to process any orders for patients for whom a vaccination has not been confirmed.
Instructions on how to confirm that your patient has been vaccinated and to complete the Declaration of Vaccination are available at: https://hcp.zilucoplancap.eu/grc
